Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Obinutuzumab, Ibrutinib, and Venetoclax for Relapsed and Previously Untreated Chronic Lymphocytic Leukemia (CLL)

NCT02427451 is registered in ClinicalTrials.gov with Kerry Rogers as lead sponsor.

NCT NCT02427451
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02427451 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Obinutuzumab, Ibrutinib, and Venetoclax for Relapsed and Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Lead sponsor
Kerry Rogers
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
August 3, 2015
Completion date
April 15, 2027
Enrollment
87 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia, refractory chronic lymphocytic leukemia